Thoratec Corp.
Thoratec recall gets FDA’s highest-risk label following injuries, deaths | MassDevice.com On Call
Thoratec updates HeartMate II controller warning
What medtech companies is BlackRock buying into?
Deaths prompt Thoratec warning on HeartMate II controller switch risk
Listen to Thoratec’s Q4 2013 earnings call
Thoratec caps off 2013 and predicts healthy growth in the year to come
Thoratec shareholder seeks class action over recall, blood clot study
J.P. Morgan medtech wrap-up: Ups and downs from San Francisco
HeartWare slides on missed Q4 prelims
HeartWare International (NSDQ:HTWR) said it expects to report 4th-quarter revenues of roughly $53 million, missing the consensus view on Wall Street of $58 million and sending its share price down sharply in pre-market trading.